Docket No.: 1662/52202

Amendments to the Claims:

1. (Currently amended) A composition for local administration of anti-tumor chemotherapeutic to a patient having a tumor, the composition comprising:

a plurality of microspheres incorporating at least one anti-tumor chemotherapeutic; and

a suspending solution comprising at least one apoptosis-inducing chemotherapeutic combined with an amount of a plasma protein effective in increasing the aqueous solubility of the apoptosis-inducing chemotherapeutic in the suspending solution.

- 2. (Canceled)
- 3. (Currently amended) The composition of claim 21, wherein the plasma protein is selected from the group consisting of human serum albumin, γ -immunoglobulin, and combinations thereof.
- 4. (Previously presented) The composition of claim 1, wherein the longest diameter of the microspheres is less than about 20 microns.
- 5. (Previously presented) The composition of claim 1, wherein the microspheres are microcapsules.
- 6. (Previously presented) The composition of claim 1, wherein the anti-tumor chemotherapeutic is contained within the microsphere.
- 7. (Previously presented) The composition of claim 1, wherein the anti-tumor chemotherapeutic is attached to the microsphere.
- 8. (Previously presented) The composition of claim 1, wherein the microspheres comprise at least one biodegradable polymer.
- 9. (Previously presented) The composition of claim 8, wherein the biodegradable polymer is selected from the group consisting of polylactic acid, polyglycolic acid and a copolymer of polyglycolic and polylactic acid.
- 10. (Withdrawn) The composition of claim-2, wherein the microspheres comprise a non-

Docket No.: 1662/52202

biodegradable polymer.

- 11. (Withdrawn) The composition of claim 2, wherein the non-biodegradable polymer is an ethylene vinyl acetate copolymer.
- 12. (Previously presented) The composition of claim 2, wherein degradation of the microspheres releases the anti-tumor chemotherapeutic in a therapeutically effective amount.
- 13. (Original) The composition of claim 12, wherein up to about 50 % of the anti-tumor chemotherapeutic is released from the microspheres within about 24 hours after administration of the microspheres to the patient.
- 14. (Original) The composition of claim 12, wherein between about 15 to about 25 % of the anti-tumor chemotherapeutic is released from the microspheres within about 24 hours after administration of the microspheres to the patient.
- 15. (Previously amended) The composition of claim 12, wherein the anti-tumor chemotherapeutic is released from the microsphere by diffusion.
- 16. (Original) The composition of claim 15, wherein the anti-tumor chemotherapeutic is released in a therapeutically effective amount over a period of time from about 1 week to about six months after administration to the patient.
- 17. (Original) The composition of claim 15, wherein the anti-tumor chemotherapeutic is released in a therapeutically effective amount over a period of time from about 3 weeks to about 2 months after administration to the patient.
- 18. (Previously presented) The composition of claim 1, wherein the anti-tumor chemotherapeutic comprises at least one apoptosis inducing chemotherapeutic.
- 19. (Withdrawn) The composition of claim 18,-wherein the apoptosis inducing chemotherapeutic-is-selected from the group consisting of cisplatin, adriamycin, butyric acid, cyclophosphamide, etoposide, amsacrine, genistein, and mitoguazone.
- 20. (Previously presented) The composition of claim 18, wherein the microspheres comprise paclitaxel.

Docket No.: 1662/52202

- 21. (Original) The composition of claim 20, wherein the paclitaxel is at a concentration from about 0.1 to about 10 mg/mL.
- 22. (Original) The composition of claim 20, wherein the paclitaxel is at a concentration from about 0.5 to about 5 mg/mL.
- 23. (Canceled)
- 24. (Previously presented) The composition of claim 1, wherein the suspending solution contains paclitaxel.
- 25. (Previously presented) The composition of claim 24, wherein the total paclitaxel in the composition is about 70 to about 280 mg.
- 26. (Original) The composition of claim 24, wherein the paclitaxel in both the microspheres and in the solution is at a concentration of about 135 mg/m² to about 175 mg/m².
- 27. (Previously presented) The composition of claim 24, wherein about 10 % to about 90 % of the paclitaxel is incorporated in the microspheres.
- 28. (Previously presented) The composition of claim 27, wherein about 60 % to about 90 % of the paclitaxel is incorporated in the microspheres.
- 29. (Previously presented) The composition of claim 28, wherein about 80 % to about 90 % of the paclitaxel is incorporated in the microspheres.
- 30. (Canceled)
- 31. (Canceled)
- 32. (Previously presented) The composition of claim 24, wherein the suspending solution comprises an anti-tumor chemotherapeutic selected from the group consisting of paclitaxel, cisplatin, adriamycin, butyric acid, cyclophosphamide, etoposide, amsacrine, genistein, and mitoguazone.
- 33. (Currently amended) A method for local administration of an anti-tumor chemotherapeutic to a tumor, comprising the steps of:

delivering to a tumor a chemotherapeutic reservoir comprising (1) a plurality of microspheres incorporating at least one anti-tumor chemotherapeutic and (2) a

Docket No.: 1662/52202

suspending solution comprising at least one apoptosis-inducing chemotherapeutic combined with an amount of a plasma protein effective in increasing the aqueous solubility of the apoptosis-inducing chemotherapeutic in the suspending solution.

- 34. (Canceled)
- 35. (Currently amended) The method of claim $\frac{34}{33}$, wherein the plasma protein is selected from the group consisting of human serum albumin, γ -immunoglobulin, and combinations thereof.
- 36. (Previously presented) The method of claim 33, wherein the microspheres comprise at least one biodegradable polymer.
- 37. (Previously presented) The method of claim 36, wherein the biodegradable polymer is selected from the group consisting of polylactic acid, polyglycolic acid and a co-polymer of polyglycolic and polylactic acid.
- 38. (Withdrawn) The method of claim 34, wherein the microspheres comprise a non-biodegradable polymer.
- 39. (Withdrawn) The method of claim 38, wherein the non-biodegradable polymer is a ethylene-vinyl acetate copolymer.
- 40. (Previously presented) The method of claim 33, wherein the anti-tumor chemotherapeutic is released from the microspheres in a therapeutically effective amount primarily by degradation of the microspheres.
- 41. (Previously presented) The method of claim 40, wherein about 50 % of the anti-tumor chemotherapeutic is released from the microspheres within about 24 hours following delivery of the chemotherapeutic reservoir to the tumor.
- 42. (Previously presented) The method of claim 40, wherein about 15 to about 25 % of the anti-tumor chemotherapeutic is released from the microspheres within about 24 hours following delivery of the chemotherapeutic reservoir to the tumor.
- 43. (Previously presented) The method of claim 34, wherein the anti-tumor chemotherapeutic is released from the microsphere primarily by diffusion.

PATENT Docket No.: 1662/52202

- 44. (Original) The method of claim 43, wherein the anti-tumor chemotherapeutic is continuously released from the microspheres in a therapeutically effective amount for a time period lasting from between about one week to about six months.
- 45. (Original) The method of claim 43, wherein the anti-tumor chemotherapeutic is continuously released from the microspheres in a therapeutically effective amount for a time period lasting from between about three weeks to about two months.
- 46. (Previously presented) The method of claim 33, wherein the longest diameter of the microspheres are less than about 20 microns.
- 47. (Previously presented) The method of claim 33, wherein the microspheres are microcapsules.
- 48. (Previously presented) The method of claim 33, wherein the microspheres comprise at least one apoptosis inducing chemotherapeutic.
- 49. (Withdrawn) The method of claim 48, wherein the apoptosis inducing chemotherapeutic is selected from the group consisting of cisplatin, adriamycin, butyric acid, cyclophosphamide, etoposide, amsacrine, genistein, and mitoguazone.
- 50. (Previously presented) The method of claim 48, wherein the microspheres comprise paclitaxel.
- 51. (Original) The composition of claim 50, wherein the paclitaxel is at a concentration from about 0.1 to about 10 mg/mL.
- 52. (Original) The method of claim 50, wherein the paclitaxel is at a concentration from about 0.5 to about 5 mg/mL.
- 53. (Canceled)
- 54. (Previously presented) The method of claim 33, wherein the suspending solution contains paclitaxel.
- 55. (Previously presented) The method of claim 33, wherein the total paclitaxel in the composition is about 70 to about 280 mg.
- 56. (Previously presented) The method of claim 33, wherein the total paclitaxel in both the

Docket No.: 1662/52202

microspheres and in the solution is at a concentration of about 135 mg/m 2 to about 175 mg/m 2 .

- 57. (Previously presented) The method of claim 33, wherein the composition contains paclitaxel, about 10 % to about 90 % of which is incorporated in the microspheres.
- 58. (Previously presented) The method of claim 33, wherein about 60 % to about 90 % of the paclitaxel is incorporated in the microspheres.
- 59. (Previously presented) The method of claim 33, wherein about 80 % to about 90 % of the paclitaxel is incorporated in the microspheres.
- 60. (Canceled)
- 61. (Canceled)
- 62. (Previously presented) The method of claim 33, wherein the suspending solution comprises an anti-tumor chemotherapeutic selected from the group consisting of paclitaxel, cisplatin, adriamycin, butyric acid, cyclophosphamide, etoposide, amsacrine, genistein, and mitoguazone.
- 63. (Previously presented) The method of claim 33, wherein the delivering step includes the step of positioning the chemotherapeutic reservoir within the tumor.
- 64. (Previously presented) The method of claim 33, wherein the delivering step includes the step of intratumorally injecting the chemotherapeutic reservoir within the tumor.
- 65. (Previously presented) The method of claim 33, wherein the delivering step includes the step of positioning chemotherapeutic reservoir adjacent to the tumor.
- 66. (Previously presented) The method of claim 33, wherein the chemotherapeutic reservoir is delivered into the tumor with elevated pressure.
- 67. (Previously presented) The method of claim 33, further comprising a step of delivering to the tumor a solution comprising a chemotherapeutic before the step of delivering the chemotherapeutic reservoir.
- 68. (Previously presented) The method of claim 67, wherein the chemotherapeutic comprises paclitaxel.

PATENT Docket No.: 1662/52202

- 69. (Previously presented) The method of claim 67, wherein both the solution and the chemotherapeutic reservoir are delivered with elevated pressure.
- 70. (Currently amended) The method of claim 34 33, wherein the plasma protein is human serum albumin.
- 71. (Currently amended) The method of claim 2 1, wherein the plasma protein is human serum albumin.